Kenan BARUT, Mehmet YILDIZ, Fatih HAŞLAK, Özgür KASAPÇOPUR, Amra ADROVIC

Childhood Rheumatic Diseases and COVID-19 Pandemic: An Intriguing Linkage and a New Horizon

As it is known, we are all in a pandemic situation due to a novelcoronavirus, officially named “Severe Acute Respiratory SyndromeCoronavirus 2” and the disease caused by the virus named “Coronavirusdisease-2019”. The virus seems to has propensity to infect older maleindividuals with underlying disease. The clinical features were on alarge scale that varies from being an asymptomatic carrier to acuterespiratory distress syndrome and multiorgan dysfunction. Fever, drycough and fatigue are the most common symptoms. Not only, thedisease seems to be rare and have a milder course in pediatric agebut also respiratory failure, multiorgan dysfunction, and death areextremely rare. Although several comorbidities such as hypertension,diabetes and cardiovascular diseases are defined as a risk factor fordeveloping the acute respiratory syndrome and need for intensivecare; immune-compromised situations such as rheumatic diseasewhich require immunosuppressive treatment strikingly are not foundto be a risk factor for more severe disease course. However, there isa lack of data regarding the effects of “Coronavirus disease-2019”on pediatric patients with rheumatic diseases. Additionally, thereare three controversial circumstances that patients with rheumaticdiseases are believed to be more likely to have viral infections like“Severe Acute Respiratory Syndrome Coronavirus 2”, on the otherhand, antirheumatic drugs may have a protective and therapeutic rolein Coronavirus disease-2019 and children are more unlikely to haveserious disease course. Therefore, we aimed to have a contributor rolefor explaining this conundrum and present a bird’s eye view regardingthis equivocal issue in this review.

PDF

___

1. Report of clustering pneumonia of unknown etiology in Wuhan City. Wuhan Municipal Health Commission; 2019. http://wjw.wuhan.gov.cn/front/web/ showDetail/2019123108989 Accessed on April 3, 2020.
2. Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr 2020;87:281-6.
3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
4. She J, Liu L, Liu W. COVID-19 epidemic: disease characteristics in children. J Med Virol 2020 Mar 31. doi: 10.1002/jmv.25807. [Epub ahead of print]
5. Organization WH. Coronavirus disease 2019 (COVID-19): situation report, 51. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311- sitrep-51-covid-19.pdf?sfvrsn=1ba62e57_10 Accessed on April 3, 2020.
6. Sarzi-Puttini P, Giorgi V, Sirotti S, Marotto D, Ardizzone S, Rizzardini G, et al. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? Clin Exp Rheumatol 2020;38:337-42.
7. Wang Q, Qi J, Yuan Y, Xuan Y, Han P, Wan Y, et al. Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26. Cell Host Microbe 2014;16:328-37.
8. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270-3.
9. Harmer D, Gilbert M, Borman R, Clark KL. Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS Lett 2002;532:107-10.
10. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmum 2020:102433.
11. de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 2016;14:523-34.
12. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 2020;46:586-90.
13. Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R. COVID-19 infection and rheumatoid arthritis: Faraway, so close! Autoimmun Rev 2020:102523.
14. Wang W, He J, Lie P, Huang L, Wu S, Lin Y, et al. The definition and risks of Cytokine Release Syndrome-Like in 11 COVID-19-Infected Pneumonia critically ill patients: Disease Characteristics and Retrospective Analysis. Medrxiv February 27, 2020. doi: https://doi.org/10.1101/2020.02.26.20026989
15. Organization WH. Coronavirus disease 2019 (COVID-19): situation report, 74. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200403- sitrep-74-covid-19-mp.pdf?sfvrsn=4e043d03_14 Accessed on April 3, 2020.
16. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507-13.
17. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020 Feb 7. doi: 10.1001/jama.2020.1585. [Epub ahead of print].
18. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020 Feb 24. doi: 10.1001/jama.2020.2648. [Epub ahead of print].
19. Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. SARS-CoV-2 infection in children. N Engl J Med 2020;382:1663-5.
20. Ludvigsson JF. Systematic review of COVID-19 in children show milder cases and a better prognosis than adults. Acta Paediatr 2020;109:1088-95.
21. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China. Pediatrics 2020; doi:10.1542/peds. 2020-0702 0.
22. Hong H, Wang Y, Chung HT, Chen CJ. Clinical characteristics of novel coronavirus disease 2019 (COVID-19) in newborns, infants and children. Pediatr Neonatol 2020;61:131-2.
23. Brodin P. Why is COVID-19 so mild in children? Acta Paediatr 2020;109:1082-3.
24. Lee PI, Hu YL, Chen PY, Huang YC, Hsueh PR. Are children less susceptible to COVID-19? J Microbiol Immunol Infect 2020 Feb 25. pii: S1684-1182(20)30039-6. doi: 10.1016/j.jmii.2020.02.011. [Epub ahead of print].
25. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YBb, Yan YQ, et al. Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China. Allergy 2020 Feb 19. doi: 10.1111/all.14238. [Epub ahead of print].
26. Ferro F, Elefante E, Baldini C, Bartoloni E, Puxeddu I, Talarico R, et al. COVID-19: the new challenge for rheumatologists. Clin Exp Rheumatol 2020;38:175-80.
27. Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis 2020;79:667-8.
28. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med 2020;382:1787-99.
29. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30:269-71.
30. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res 2020;178:104787.
31. Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents 2020;55:105932.
32. Gandolfini I, Delsante M, Fiaccadori E, Zaza G, Manenti L, Degli Antoni A, et al. COVID-19 in Kidney Transplant Recipients. Am J Transplant 2020 Mar 31. doi: 10.1111/ajt.15891. [Epub ahead of print].
33. Tang NL, Chan PK, Wong CK, To KF, Wu AK, Sung YM, et al. Early enhanced expression of interferon-inducible protein-10 (CXCL-10) and other chemokines predicts adverse outcome in severe acute respiratory syndrome. Clin Chem 2005;51:2333-40.
34. Qiao W, Wang C, Chen B, Zhang F, Liu Y, Lu Q, et al. Ibuprofen attenuates cardiac fibrosis in streptozotocin-induced diabetic rats. Cardiology 2015;131:97-106.
35. Venerito V, Lopalco G, Iannone F. COVID-19, rheumatic diseases and immunosuppressive drugs: an appeal for medication adherence. Rheumatol Int 2020;40:827-8.
36. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020 Mar 20:105949. doi: 10.1016/j.ijantimicag.2020.105949. [Epub ahead of print].
37. Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents 2020 Mar 29:105954. doi: 10.1016/j.ijantimicag.2020.105954. [Epub ahead of print].
38. Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with Tocilizumab. Proc Natl Acad Sci U S A.2020 Apr 29. pii: 202005615. doi: 10.1073/pnas.2005615117. [Epub ahead of print]
39. Cron RQ, Chatham WW. The Rheumatologist’s Role in Covid-19. J Rheumatol 2020;47:639-42.